Spectrum Pharmaceuticals
| Spectrum Pharmaceuticals | |
| Company type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Headquarters | Henderson, Nevada, U.S. |
Key people | Joseph Turgeon, Chief Executive Officer |
| Revenue |  US$109.33 million (2018) |
Number of employees |  235 (December 31, 2018) |
| Website | sppirx |
Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.
Drugs
Spectrum develops and markets drugs for treatments in oncology.
Approved drugs
- Fusilev (Levoleucovorin) for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.[citation needed]
- Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma.
- Khapzory (levoleucovorin) (Disodium Levoleucovorin), for injection, a folate analog for three indications:
- Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
- Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination.
- The treatment of patients with metastatic colorectal cancer in combination with fluorouracil.
- Zevalin (ibritumomab) is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab-refractory follicular NHL. It is a CD-20 radio-antibody.[1]
- Marqibo (Vincristine sulfate liposomes injection) is a sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It was approved by the FDA in 2012.[2]
- Beleodaq (belinostat) is an HDAC inhibitor for relapsed or refractory peripheral T-cell lymphoma.
- Evomela (melphalan) is an alkalyating drug for multiple myeloma.[1]
In development
A number of drugs are currently investigated in clinical trials.[3]
- Qapzola (apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan invested money in 2008 to help develop this medication further and bring it to the market.[4]
- Rolontis (eflapegrastim) is in phase III trials for treatment of chemotherapy-induced neutropenia.[5]
- Poziotinib is a quinazoline-based pan-HER inhibitor that blocks signaling through HER tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4). It is currently in phase II trials.
Spectrum terminated the development of Ozarelix, a luteinizing hormone releasing hormone antagonist for the treatment of benign prostatic hypertrophy in 2010.[6] Other previous drug candidates included ortataxel for the treatment of taxane-refractory tumors, and satraplatin for non-small cell lung cancer.
References
- ^ a b [1] [dead link]
- ^ "Spectrum Pharmaceuticals Launches Marqibo® (vinCRIStine sulfate LIPOSOME injection) and Ships First Commercial Orders". Businesswire.com. 3 September 2013. Retrieved 2 June 2019.
- ^ "Search of: Recruiting, Not yet recruiting, Available Studies - spectrum pharmaceuticals - List Results". Clinicaltrials.gov. Retrieved 2 June 2019.
- ^ Marcial G (June 15, 2009). "Cancer drugs from Spectrum". Businessweek: 67.
- ^ "RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide - Full Text View". Clinicaltrials.gov. Retrieved 2 June 2019.
- ^ "Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy". Businesswire.com. 27 January 2010. Retrieved 2 June 2019.